Status:

RECRUITING

A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)

Lead Sponsor:

Biogen

Collaborating Sponsors:

Alcyone Therapeutics, Inc

Conditions:

Muscular Atrophy, Spinal

Eligibility:

All Genders

3+ years

Phase:

PHASE1

Brief Summary

In this PIERRE-PK study, researchers will learn how the body processes nusinersen when it is given through the ThecaFlex DRx™ System, compared to when nusinersen is given by lumbar puncture (LP). The ...

Detailed Description

The primary objective of this study is to assess the Pharmacokinetic (PK) profile of nusinersen delivered via standard LP and via the ThecaFlex DRx System in participants with SMA.

Eligibility Criteria

Inclusion

  • Key
  • Participant is on regular maintenance dosing of nusinersen (12 milligrams \[mg\] dose) every 4 months, with 4 months (± 2 weeks) between the LP-delivered study dose and the last nusinersen dose prior to study enrollment.
  • Participants must be enrolled in the PIERRE study to be eligible for enrolment in the PIERRE PK study.
  • Key

Exclusion

  • Ongoing participation or participation within 6 months or 5 half-lives of the agent (whichever is longer) of enrollment in other interventional clinical trials for the treatment of SMA (except for the PIERRE study or interventional clinical trials of myostatin inhibitors \[e.g., apitegromab and taldefgrobep alfa\]).
  • Participant is naïve to nusinersen treatment.
  • Participant is receiving nusinersen at a dose other than 12 mg.
  • Participant has already undergone implantation of the ThecaFlex DRx system.
  • Participant is pregnant, currently breastfeeding, or intending to become pregnant during the study.
  • NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply

Key Trial Info

Start Date :

January 16 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 15 2026

Estimated Enrollment :

58 Patients enrolled

Trial Details

Trial ID

NCT06555419

Start Date

January 16 2025

End Date

May 15 2026

Last Update

September 8 2025

Active Locations (18)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (18 locations)

1

Children's Hospital of Orange County

Orange, California, United States, 92868

2

Stanford University Medical Center | Department of Neurology_Palo Alto

Palo Alto, California, United States, 94304

3

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States, 60611-2605

4

Boston Children's Hospital

Boston, Massachusetts, United States, 02115